Carlyle expects at least $20B of Q4 inflows as it targets about $60B for full-year 2026

Nephros GAAP EPS of $0.05 beats by $0.03, revenue of $5.6M beats by $0.11M

2026/11/06

Enliven Therapeutics GAAP EPS of -$0.36

2026/11/06

Tucows Non-GAAP EPS of -$0.52, revenue of $100M

2026/11/06

Ultralife GAAP EPS of $0.14, revenue of $48.3M

2026/11/06